Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL).

Al-Sawaf O, Bazeos A, Robrecht S, Bahlo J, Gower C, Fink AM, Tresckow J, Cramer P, Langerbeins P, Kutsch N, Humphrey K, Fingerle-Rowson G, Stilgenbauer S, Wendtner CM, Fischer K, Eichhorst B, Hallek M, Goede V.

Am J Hematol. 2019 Jun 20. doi: 10.1002/ajh.25561. [Epub ahead of print]

PMID:
31222797
2.

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.

Nteliopoulos G, Bazeos A, Claudiani S, Gerrard G, Curry E, Szydlo R, Alikian M, Foong HE, Nikolakopoulou Z, Loaiza S, Khorashad JS, Milojkovic D, Perrotti D, Gale RP, Foroni L, Apperley JF.

Haematologica. 2019 Dec;104(12):2400-2409. doi: 10.3324/haematol.2018.200220. Epub 2019 May 9.

3.

Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy.

Klanova M, Oestergaard MZ, Trněný M, Hiddemann W, Marcus R, Sehn LH, Vitolo U, Bazeos A, Goede V, Zeuner H, Knapp A, Sahin D, Spielewoy N, Bolen CR, Cardona A, Klein C, Venstrom JM, Nielsen T, Fingerle-Rowson G.

Clin Cancer Res. 2019 Aug 1;25(15):4634-4643. doi: 10.1158/1078-0432.CCR-18-3270. Epub 2019 May 3.

PMID:
31053601
4.

Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.

Mughal TI, Vannucchi AM, Soverini S, Bazeos A, Tibes R, Saglio G, Abdel-Wahab O, Pardanani A, Hehlmann R, Barbui T, Van Etten R, Tefferi A, Goldman JM.

Haematologica. 2014 May;99(5):797-801. doi: 10.3324/haematol.2013.097832. Review. No abstract available.

5.

Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.

de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, Mielke S, Bazeos A, Stringaris K, Ali S, Milojkovic D, Foroni L, Chaidos A, Cooper N, Gabriel I, Apperley J, Belsey S, Flanagan RJ, Goldman J, Shpall EJ, Kelleher P, Marin D, Rezvani K.

Blood. 2013 Jul 11;122(2):227-38. doi: 10.1182/blood-2012-11-465039. Epub 2013 May 29.

6.

Buccals are likely to be a more informative surrogate tissue than blood for epigenome-wide association studies.

Lowe R, Gemma C, Beyan H, Hawa MI, Bazeos A, Leslie RD, Montpetit A, Rakyan VK, Ramagopalan SV.

Epigenetics. 2013 Apr;8(4):445-54. doi: 10.4161/epi.24362. Epub 2013 Mar 28.

7.

Biology of CML stem cells: the basis for clinical heterogeneity?

Goldman JM, Gordon M, Bazeos A, Marin D.

Leuk Suppl. 2012 Aug;1(Suppl 2):S43-5. doi: 10.1038/leusup.2012.23. Epub 2012 Aug 9.

8.

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.

Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D.

Blood. 2011 Apr 7;117(14):3733-6. doi: 10.1182/blood-2010-10-309807. Epub 2011 Feb 23.

9.

Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib.

Powles T, Chowdhury S, Shamash J, Bazeos A, Gillessen S, Saunders N, Lim L, Sarwar N, Sadev A, Wilson P, Nathan P, Boleti K, Peters J, Agrawal S.

Ann Oncol. 2011 Apr;22(4):815-20. doi: 10.1093/annonc/mdq469. Epub 2010 Oct 13.

PMID:
20943595
10.

hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.

Bazeos A, Marin D, Reid AG, Gerrard G, Milojkovic D, May PC, de Lavallade H, Garland P, Rezvani K, Apperley JF, Goldman JM, Foroni L, Khorashad JS.

Leukemia. 2010 Jun;24(6):1243-5. doi: 10.1038/leu.2010.86. Epub 2010 May 6. No abstract available.

PMID:
20445576
11.

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS.

J Clin Oncol. 2010 May 10;28(14):2381-8. doi: 10.1200/JCO.2009.26.3087. Epub 2010 Apr 12.

12.

Application of camera phones in telehaematology.

McLean R, Jury C, Bazeos A, Lewis SM.

J Telemed Telecare. 2009;15(7):339-43. doi: 10.1258/jtt.2009.090114.

PMID:
19815902
13.

The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease.

Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, Gazzard B, Bower M.

Ann Oncol. 2009 Apr;20(4):775-9. doi: 10.1093/annonc/mdn697. Epub 2009 Jan 29.

PMID:
19179554
14.

Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation.

Mattes FM, Vargas A, Kopycinski J, Hainsworth EG, Sweny P, Nebbia G, Bazeos A, Lowdell M, Klenerman P, Phillips RE, Griffiths PD, Emery VC.

Am J Transplant. 2008 May;8(5):990-9. doi: 10.1111/j.1600-6143.2008.02191.x. Epub 2008 Mar 4. Erratum in: Am J Transplant. 2011 May;11(5):1107.

15.

HIV-associated Castleman's disease: from case reports to evidence.

Bazeos A, Powles T, Stebbing J.

J HIV Ther. 2007 Sep;12(3):61-2. No abstract available.

PMID:
17962792
16.

Are Helicobacter species and enterotoxigenic Bacteroides fragilis involved in inflammatory bowel disease?

Basset C, Holton J, Bazeos A, Vaira D, Bloom S.

Dig Dis Sci. 2004 Sep;49(9):1425-32.

PMID:
15481314

Supplemental Content

Loading ...
Support Center